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Abstract
Cysteine-richintestinal protein 1(CRIP1)has been identifiedas a novelmarkerforearly detectionof cancers. Here wereporton
the use of phage display in combination with molecular modeling to identify a high-affinity ligand for CRIP1. Panning
experiments using a circularized C7C phage library yielded several consensus sequences with modest binding affinities to
purified CRIP1. Two sequence motifs, A1 and B5, having the highest affinities for CRIP1, were chosen for further study. With
peptide structure information andthe NMRstructure of CRIP1,the higher-affinity A1 peptidewas computationallyredesigned,
yieldinga novelpeptide, A1M, whoseaffinity waspredictedtobemuchimproved. Synthesisofthepeptide and saturation and
competitive binding studies demonstrated approximately a 10–28-fold improvement in the affinity of A1M compared to that
of either A1 or B5 peptide. These techniques have broad application to the design of novel ligand peptides.
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Introduction
Cysteine-rich intestinal protein 1 (CRIP1) belongs to the LIM/
double zinc finger protein family, which includes cysteine- and
glycine-rich protein-1, rhombotin-1, rhombotin-2, and rhombotin-
3. Human CRIP1, primarily a cytosolic protein, was cloned in 1997
[1] using RT-PCR of human small intestine RNA and oligonucle-
otides whose sequence was derived from the human heart homolog
of this protein, CRHP [2]. Recently CRIP1 has been identified as a
very exciting biomarker for human breast cancers [3,4], cervical
cancers [5,6], pancreatic cancers [7,8] and potentially other cancers
[4,9]. In experiments comparing CRIP1 expression in human
breast cancer to matched normal breast tissue the mRNA for this
target was overexpressed 8–10-fold in approximately 90% of both
invasive and ductal carcinoma in situ [3]. Furthermore, in situ
hybridization studies demonstrated close association of the
expression with the ductal carcinoma cells [3]. CRIP1 overexpres-
sion has also been demonstrated to be the most highly differentially
expressed gene in invasive cervical carcinomas; 100-fold up-
regulation relative to normal cervical keratinocytes measured in
34 cervical tissues from different clinically defined stages [5,6].
CRIP1 was also found to have high levels of expression in
pancreatic adenocarcinoma, lung cancers and colorectal cancers
[7–9]. These data strongly support the development of imaging
probes targeting CRIP1 to improve cancer detection.
Phage display technology is a robust methodology for
identifying peptides that bind relatively tightly to target proteins.
This is especially true if the targeted protein’s function is to bind
peptides in vivo. In these applications, the first generation peptides
have a generally lower Kd (10–100 mM) for their target and
typically need to be structurally altered to improve binding before
the peptides exhibit robust binding suitable to image the target
protein. If structural data for the targeted protein exists, it should
be feasible to utilize the data to help redesign in silico the Phage
display-identified peptides thereby increasing their binding affinity.
This approach is much more cost efficient than exhaustive
screening of structured phage libraries or expansion of screening
assays to include other types of phage display libraries.
Despite the potential utility of CRIP1 [10] as an imaging target,
significant efforts to develop CRIP1-specific ligands have not been
attempted. Here we utilized phage display techniques [11–20] to
identify peptide ligands with micromolar binding affinity for
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[21–27] to increase the peptide’s binding affinity. This approach
has yielded a peptide that has approximately 10–28-fold improved
binding affinity as measured by in vitro saturation and competitive
binding assays. This study is a significant advance to the ultimate
goal of synthesizing imaging probes that report CRIP1 expression
levels in vivo.
Results
We used phage display technology to identify peptides that bind
relatively tightly to CRIP1. Then, we utilized NMR structural data
of CRIP1 and computational methods to increase the peptide
binding affinity to CRIP1.
Expression of CRIP1 and Identification of Binding
Peptides
CRIP1 was initially cloned into a mammalian expression vector
and subsequently into pHAT10 for expression in bacteria. The
pHAT10/CRIP1 vector encodes a naturally occurring polyhisti-
dine epitope tag with the sequence of nonadjacent histidines that
enable purification of expressed proteins under native conditions
at neutral pH 7.0 (details of construct can be found in Figure S1
and Figure S2). Bacterial expression was chosen since it is a robust
expression system and presumably CRIP1 does not require post-
translational modifications for function. Cultures derived from
these bacteria were induced to express CRIP1 using IPTG. We
then isolated purified CRIP1 (see Methods). SDS-PAGE analysis
of the cell lysate and fractions containing eluted CRIP1 show a
single band for chimeric CRIP1 running approximately at the
calculated molecular weight for the chimeric protein, 12.8 KDa
(Figure S2 and Table S1). The yield of CRIP1 protein was
approximately 10 mg of recombinant protein per liter of culture.
In order to generate CRIP1 protein that was as similar as
possible to endogenous CRIP1, enterokinase cleavage was
performed on purified CRIP1. Uncleaved contaminating HIS-
tagged CRIP1 as well as HIS-tagged peptides were removed by re-
running the digest over the CellThru resin and retaining the flow
thru. This manipulation of the chimeric protein resulted in a
polypeptide almost completely devoid of other ‘‘non-CRIP1’’
amino acids and was used as the bait for phage display studies.
After four rounds of positive selection against enterokinase-
truncated CRIP1, 29 phage DNA inserts were sequenced using
a 96 gIII primer (59-
HOCCC TCA TAG TTA GCG TAA CG-39).
Sequencing verified that 18 of the 29 phagotopes were from the
cysteine-constrained phage library, Table 1. Many of the peptide
sequences contained similar motifs and six sequences occurred in
more than one phagotope. The peptides A1 and C5 were
identified four times, C1 three times, and A9, B1, and B5 twice.
However, even accounting for conserved amino acid substitutions,
no clear motif could be identified.
To select clones for further analysis, we used ELISA to
determine the relative binding affinities of selected individual
phage clones to purified CRIP1 (see Methods and Figure S3). For
these studies the purified chimeric CRIP1 was not reacted with
enterokinase. Clone A1 and Clone B5 were measured to possess
higher relative affinity. Although it occurred with the same
frequency as clone A1, clone C5 exhibited lower binding affinity.
With these results, inserts from the two clones with the highest
affinities (A1 and B5) were further investigated as potential ligands
to CRIP1.
Molecular Modeling
The computational optimization of the binding affinity of the
peptide initially identified from phage display involved three
stages. We first constructed a structural model of the cyclic peptide
A1, and then we identified putative binding sites on CRIP1 by
docking. Lastly, we searched for new peptide sequences that
optimize the stability of the peptide-CRIP1 complex.
Author Summary
Breast cancer is one of the most frequently diagnosed
malignancies in American females and is the second
leading cause of cancer deaths in women. Several
improvements in diagnostic protocols have enhanced
our ability for earlier detection of breast cancer, resulting
in improvement of therapeutic outcome and an increased
survival rate for breast cancer patients. However, current
early screening techniques are neither comprehensive nor
infallible. Imaging techniques that improve breast cancer
detection, localization, and evaluation of therapy are
essential in combating the disease. Cysteine-rich intestinal
protein 1 (CRIP1) has been identified as a novel marker for
early detection of breast cancers. Here, we report the use
of phage display and computational molecular modeling
to identify a high-affinity ligand for CRIP1. Phage display
panning experiments initially identified consensus peptide
sequences with modest binding affinity to purified CRIP1.
Using ab initio modeling of binding peptide structures,
computational docking, and recently developed free
energy estimation protocols, we redesigned the peptides
to increase their affinity for CRIP1. Synthesis of the
redesigned peptide and binding studies demonstrated
approximately a 10–28-fold improvement in the binding
affinity. The combination of computational and experi-
mental techniques in this study demonstrates a potentially
powerful tool in modulating protein–protein interactions.
Table 1. Peptide sequences that were enriched after phage
display panning experiments.
ID Sequence Frequency
A1
a LKDNHRS 4
A3 SVPINDS 1
A5 DHRQGSS 1
A6 APYNTLA 1
A8 SPHIIAS 1
A9
a MLHAYAQ 2
B1
a FLGFSQQ 2
B2 YDPIWRT 1
B3 FSTNMKT 1
B4 RTTGAQT 1
B5
a YDPIWRT 2
B7 PLFKGMS 1
B9 LPAYSTY 1
B10 RDSSAHQ 1
C1
a CYTAALA 3
C2 HANFLHM 1
C5
a TPRQSPI 4
C9 SLNTRSQ 1
aThe sets of identical sequences derived from different phage clones.
doi:10.1371/journal.pcbi.1000138.t001
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A1 (see Methods). To remove the bias on the docking that may be
introduced by using only one backbone peptide conformation, we
first generated several peptide backbone conformations from
snapshots of equilibrium molecular dynamics simulations. Each
peptide was docked to the 48 conformations of CRIP1 derived
from NMR [10]. By clustering the location of the peptides on the
CRIP1 surface, we were able to identify and rank the putative
binding sites (Figure 2). Interestingly, the peptides preferably bind
to one face of CRIP1 (Figure 2). This side of CRIP1 contains two
grooves, one formed by helix H3 and S6–S7 loop and another by
S2–S3 loop and the N-terminal loop. The binding site of the
successfully redesigned A1M is formed by Glu46, His45, Phe60,
Tyr56, and Lys48 (Figure 3).
In the second stage of the redesign, we searched for peptide
sequences that optimized the binding free energies of the peptide-
CRIP1 complexes using heuristic algorithms and a physical force-
field (see Methods). The methodology employs rapid side-chain
packing and backbone relaxation to calculate the free energy
change due to a mutation. For a given CRIP1-peptide complex,
we determined a set of mutations in the bound peptide that
resulted in the lowest free energy change, and thus, the highest
predicted increase in binding affinity. All CRIP1-peptide com-
plexes were subjected to redesign. All redesigned peptides were
then grouped according to their starting peptide backbone
conformation (1-ns, 9-ns, or 10-ns), and according to their putative
binding site. The redesigned sequence CLDGGGKGC, which we
denote here as A1M (‘‘modified A1’’), corresponds to a peptide
with the lowest binding free energy DDG among the redesigned
sequences in the highest-ranked binding mode. In Table 2 we list
representative peptide sequences with high binding affinity but
located in other putative binding sites and featuring backbone
conformations other than the 1-ns.
To identify the dominant motifs in the redesigned peptides, we
show in Figure S5 the dominant sequence motifs in the top three
candidates binding sites for each peptide model. There is a
prevalence of Gly, presumably due to the strongly curved backbone
that prefers more flexible Gly over any other residue when the
peptide is in the context of the protein but not when the peptide is
isolated (Figure S6). The redesigned sequences also exhibit a
preference forchargedresidues(mostly Asp, Glu,andLys)inat least
two positions (Figure S5). These charged residues, we believe, are
what attributes the redesigned peptides their specificity to CRIP1.
In particular, the designed sequence A1M (Figure S5), which is a
member of the largest cluster in the CRIP1 and 1-ns peptide
complexes, exhibits a preference for either Lys or Glu in the 2
nd
position, Asp in the 5
th, Lys in the 7
th, and Gly in the rest.
A closer inspection of the specific energy contributions to the
DDG of A1M (Table S2), we found that the largest contributions to
DDG arises from more favorable van der Waals interaction
between the peptide and CRIP1, which we believe is reflected in
the preference for Gly in some sites of the binding peptide. The
CRIP1-peptide complex also exhibits more favorable solvation
energy after the redesign. This observation is also reflected
structurally in Figure 3. In particular, the peptide side chains in A1
(such as 4D, 5N, 6H, and 8S) that point toward the CRIP1 surface
are replaced by Gly, while those pointing to solution (3K and 7R)
retain their polar nature.
Binding Affinity
We computationally redesigned A1 resulting in a peptide with a
new sequence (denoted as A1M) predicted to bind to CRIP1 with
Figure 1. CRIP1 and the designed biomarker. (A) CRIP1 is composed of 2 LIM domains and a C-terminal loop that is unstructured. (B) The
designed CRIP1 probe consists of a cyclic ligand peptide with a fluorescent molecule. (C) Cyclic peptide model corresponding to A1 derived from
phage display experiments.
doi:10.1371/journal.pcbi.1000138.g001
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were all synthesized and labeled with FITC for binding studies.
Since the peptides encoded by the C7C phage library are at the N-
terminus of the minor phage coat protein pIII followed by a short
phage encoded spacer Gly-Gly-Gly-Ser, we included this 4-mer in
the synthesized peptide. An additional C-terminal Lys was also
included in order to enable fluorescent labeling of the peptide.
Thus, the different selected mimotopes were produced as synthetic
peptides with Gly-Gly-Gly-Ser-Lys and then labeled by adding a
fluorescent molecule to the C-terminal lysine. We synthesized the
cyclic form of the peptides, A1, B5 and A1M and determined their
ability to bind CRIP1 using saturation binding experiments. The
value for the apparent equilibrium dissociation constant (Kd
apparent) of the FITC-A1M peptide determined by saturation
binding was 2.6 mM, Figure 4A. This was substantially lower than
that obtained for either the parent A1 peptide (Kd apparent =
34.4 mM) or the estimate for the Kd apparent of the B5 peptide (Kd
apparent = 62.5 mM) derived using similar assays, data not shown.
To directly compare the affinity of the A1 and A1M peptides for
CRIP1 protein, we performed a competitive binding assay and
Figure 2. Putative binding sites on CRIP1. Three peptide models 1-ns, 2-ns, and 3-ns were docked onto the CRIP1 structure. The centers of mass
of each peptide’s Ca atoms are shown as spheres on the CRIP1 surface. The binding poses of each peptide model were clustered to determine
putative binding sites. Spheres that belong to the same cluster are colored similarly. The largest cluster of docked 1-ns peptides, which is also the
binding site of A1M (Figure 3), is shown with an arrow. On the left panel, we plot the number of clusters and the size of the largest cluster to
determine the optimal cutoff for clustering. The final cutoff used in the clustering is shown by an arrow.
doi:10.1371/journal.pcbi.1000138.g002
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the ligand. These studies demonstrated that the binding affinity of
the A1M peptide to CRIP1 was approximately 27.5 times better
than that of the original A1 peptide, Figure 4B (A1 peptide IC50 =
8.8 mM, A1M peptide IC50 = 0.32 mM). Since each peptide was
effective at displacing FITC-A1M and reached the same minimal
binding these data also suggest that ligand binding to CRIP1
occurs at a single site. Further analysis of the binding data with
multiple binding site models clearly showed that the best fit of the
data was obtained with a one binding site model. Both
experimental results are further supported by the predicted
binding sites for each peptide to CRIP1 as depicted in Figure 3.
Interestingly, when the Ki for the A1M peptide is calculated (Ki =
0.067 mM), it is not the same as the apparent Kd for FITC-A1M
(Kd = 2.6 mM) determined by saturation binding experiments.
Based on this observation, the FITC label likely reduces the
affinity of the peptide for CRIP1, which is not uncommon with
labeled peptides. However, this observation does not alter the
interpretations of the data comparing the affinity of the unlabeled
peptides A1 and A1M.
From the apparent equilibrium dissociation constants, we
calculate the experimental free energy change to be DDG = RT
ln Kd,A1M 2 RT ln Kd,A1 = 21.6 kcal mol
21, which is smaller
than the estimated computational free energy change DDG =
283 kcal mol
21 (Table 2). This difference between the experi-
mental and computational free energy changes is primarily
contributed by the van der Waals repulsion term (Table S2),
suggesting initial clashes in the docking of the A1 peptide to the
CRIP1 structure. However, since the docking protocol (ZDOCK)
is consistently implemented, we still expect strong correlation
between the computational and experimental free energy changes,
that is, those redesigned peptides with lower computational DDG is
also expected to have low experimental DDG, although the
absolute values may not be directly comparable. In a separate
Figure 3. Peptide Redesign. (A) A1 peptide docked to groove formed by the S6–S7 turn and the helix H3 (left panel). CRIP 1 residues that form the
putative A1 binding site (right panel). (B) Redesigned A1 (A1M) peptide that is predicted to have a higher affinity to CRIP1.
doi:10.1371/journal.pcbi.1000138.g003
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and computational DDG values exhibited a correlation of 0.75
(P=10
2108).
Discussion
CRIP1 is an extremely compelling marker to exploit for
enhanced detection of breast and other cancers. However, its
cytosolic expression makes it hard to measure by conventional
means, e.g., antibodies. The cell membrane increases the
pharmacological barriers that must be overcome to bind and
consequently image the expression of this protein in cancer cells.
Thus, we developed methodologies to generate high affinity
peptides to purified cytosolic proteins with the ultimate aim of
designing these peptides to cross membranes and serve as imaging
ligands. To rapidly identify peptides that will bind to CRIP1, we
utilized phage display technology and purified CRIP1 protein.
This technology identifies relatively low affinity (10–100 mM)
ligands to target proteins. To increase the affinity of the peptides
identified using phage display, we developed a protocol for
rational peptide redesign that utilizes computational techniques.
This protocol successfully increased peptide affinity by approxi-
mately 10–28-fold.
Computational design methods have been employed to
modulate protein-protein interactions. Major challenges in protein
design include (1) identification of ligand-peptide binding site and
(2) optimization of affinity of the peptides that bind to that
particular protein [30]. In practice, sequence and conformational
space need to be adequately sampled [30]. There is also the need
for accurate energy functions that identifies protein sequences
corresponding to the global free energy minimum of a given
protein conformation [30]. Several studies have been reported to
identify protein interaction specificity [31–35]. For example,
Shifman and Mayo computationally redesigned the promiscuous
binding site of calmodulin to increase its specificity to one of its
ligand peptides [36]. The authors performed iterative optimization
of the rotamers. In another study, Reina et al. computationally
engineered a small protein-protein interaction motif of the PDZ
domain to bind novel target sequences [37]. The study
demonstrated that by combining different backbone templates
with computer-aided protein design, PDZ domains could be
engineered to specifically recognize a large number of proteins
[37]. Another example of successful redesign was the engineering
of coiled-coil interfaces that direct the formation of either
homodimers or heterodimers [38]. The design protocol involved
both positive design, stabilization of desired interaction, and
negative design, the destabilization of undesired interactions [38].
Theproblemofredesigningligandpeptidesinitiallyidentifiedfrom
phage display is challenging because the structure of the peptides are
not known and the peptides do not have a known binding site in
CRIP1. While there have been successes in the redesign of protein-
protein interfaces and location of binding site through computational
docking, there is yet no study where the system being designed face
these two major challenges simultaneously. We computationally
modeled the cyclic peptide and performed molecular dynamics to
find the equilibrium conformation of the peptide. To diversify the
backbone conformation of the peptide included in the redesign, we
selected 3 peptides from the equilibrium molecular dynamics and
docked them to 48 CRIP1 conformations from NMR. Interestingly,
Figure 4. Binding affinity of the ligand peptides to CRIP1 from
saturation binding (apparent Kd) and from competitive binding
(IC50). (A) The apparent Kd for binding of FITC-A1M to CRIP1 protein
was determined by a saturation binding experiment using 1 mM of
unlabeled A1M peptide to assess non-specific binding, Kd apparent =
2.6 uM. Error bars represent the S.E. of the corrected mean. (B) To
compare the binding affinity of A1M and A1 to CRIP1 we performed a
competitive binding assay. The concentration of the labeled ligand
(FITC-A1M) was held constant and increasing concentrations of either
unlabeled A1M or unlabeled A1 peptides were used to compete the
binding. From these binding curves regression analysis was used to
calculate the IC50 for each of the competitors. Both peptides competed
off FITC-A1M suggesting that there is only a single binding site for this
peptide on the CRIP1. A1M was approximately 27.5 times more
effective than A1 at competing for FITC-A1M binding to CRIP1. Error
bars represent S.E. of the corrected mean.
doi:10.1371/journal.pcbi.1000138.g004
Table 2. Peptide sequences determined by molecular
modeling.
Design ID Sequence DDG (kcal/mol)
Peptide
model
Binding
mode rank
a
M1 CLDGGGKGC 283 1-ns 1
M2 CLGGEKGGC 263 10-ns 4.5
b
M3 CGNDAGLGC 255 10-ns 4.5
M4 CVGNSEPGC 226 9-ns 8
M5 CGDKKQGGC 224 9-ns 4.5
All docked peptide structures were subjected to the redesign protocol. Shown
below are representative redesigned sequences from different peptide
backbone conformations (1-ns, 9-ns, or 10-ns) and from different binding sites.
The peptide A1M (CLDGGGKGC) exhibited both a high binding mode rank and
al o wDDG value; thus we select it for experimental testing.
aBinding mode rank pertains to the order of the cluster size to which the
peptide complex belongs. A binding mode of rank 1 implies that the peptide is
positioned on the site to which most other structures are also docked.
bM2 and M3 come from different binding sites but with equal number of
docked peptides.
doi:10.1371/journal.pcbi.1000138.t002
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tion is sufficient to identify putative binding sites on the protein. We
believe that the cyclic structure of the peptide was an important factor
to the success of the procedure, because the error from enthalpy-
entropy compensation is reduced when docking a cyclic peptide
compared to docking a linear peptide.
Another important factor that contributed to the success of the
peptide design is the conformational sampling introduced in the
design steps to maximize the coverage of sequence-structure space
available to the CRIP1-peptide complex. First, we performed
multiple docking simulations that allowed us to identify various
poses for binding. Second, we allowed backbone of the peptide to
be flexible during sequence design procedure, thereby significantly
diversifying the designed sequences [28,29]. Hence, the combina-
tion of the restricted conformational space available to a peptide
due to circularization and our flexible-backbone sampling
technique [28,29] allowed us to sufficiently sample the conforma-
tional space of the peptide during design, thereby contributing to a
successful peptide binder to CRIP1. Our approach can be further
extended to other systems of interest.
In this study, we combine empirical and computational
approaches to develop a novel paradigm to improve ligand affinity
when limited structural information is available. CRIP1, a
potentially powerful biomarker for several cancers, was purified
and used in an empirical phage display assay to identify short amino
acid peptides with modest affinity for the protein. The resulting
peptides were then structurally modeled, based on the structures of
other knownbutunrelated peptides ofsimilar size. Using thelimited
NMR structure available for CRIP1 the modeled peptides were
then computationally docked to CRIP1 resulting in identification of
several potential structural motifs responsible for the binding
interaction. The modeled interactions were then optimized and
peptides were redesigned based on these data.
Interestingly, even after 4 rounds of phage display isolation, no
consensus sequence for CRIP1 binding peptides emerged. These data
might possibly suggest that a strong binding ‘‘natural’’ peptide didnot
exist on the CRIP1 protein. Remarkably, however, computational
manipulation of the amino acids contained within the peptide, based
on energy minimization, significantly increased the affinity of the
peptide. This suggests that: (1) conditions for phage-CRIP1 binding
were not optimal for peptide identification; (2) the phage library did
not contain all possible combinations of amino acids; and/or (3) the
library was not exhaustively screened. In any of these cases, however,
the use of computational redesign combined with empirically derived
initial binding data significantly improved the quality of final peptide
ligands. As our database of redesigned peptides and resulting Kd’s
accumulates, the approaches described here potentially can be
generalized and could be implemented for peptide ligand generation
routinely. The resulting peptide from these studies, A1M, will be
further developed as an imaging probe.
Methods
Construction of Vectors pHat10-CRIP1 and
Transformation into E. coli
The coding region of the CRIP1 cDNA was removed from
CRIP1 in pcDNA3.1+ using BamH1 and Xba1 restriction enzymes
and subsequently subcloned into the BamHI and EcoRI sites of the
vector pHAT10 (BD Clontech) which contains an N-terminal
histidine affinity tag. The construct was confirmed by sequencing.
CRIP1 Protein Expression and Purification
Bacterial cells expressing the pHAT10-CRIP1 were cultured in
LB media containing 50 mg/ml ampicillin until reaching OD of
0.6 at which time they were induced to express the protein by
adding IPTG to a final concentration of 0.5 mM IPTG. The
bacteria were then harvested and resuspended in Equilibration/
Wash Buffer (50 mM sodium phosphate pH 7.0, 300 mM NaCl)
containing 0.75 mg/ml lysozyme and 0.0174 mg/ml PMSF and
sonicated with three 10 s pulses (medium power, Sonic Dismem-
brator Model 100, Fisher Scientific), with a pause for 30 s on ice
between sonication cycles. Following sonication, the lysates were
cleared by centrifugation, and incubated with TALON CellThru
Resin (BD Biosciences, Palo Alto, CA) in Extraction/Wash Buffer.
The tagged protein was eluted from the washed column with
0.15 M imidazole in Extraction/Wash Buffer. The purity of
CRIP1 in fractions was confirmed by SDS-PAGE [39]. The
concentration of CRIP1 in fractions was determined by Bradford
Assay using IgG as a standard [40].
Phage Display
CRIP1 was digested with enterokinase (Roche Diagnostics, Inc.)
to remove the His tag and then was used as bait for 4 rounds of
panning with the Ph.D.-C7C Phage Display Peptide Library (New
England Biolabs). The nucleotide sequence of the gene III insert
was determined by sequencing the phage, and the amino acid
sequence of the insert was deduced from the nucleotide sequence,
shown in Table 1.
Molecular Modeling and Redesign
Computational optimization of the peptide binding affinities
consists of three major steps: (1) structural modeling of cyclic
peptides initially identified from phage display experiments, (2)
finding putative binding sites of the peptides on CRIP1, and (3)
searching for sequences that optimize the stability of the peptide-
CRIP1 complex.
Peptide model. We first constructed a linear peptide model
of A1. To circularize the linear peptide, we assigned a disulfide
bond between the sulfur atoms of the terminal cysteines and
performed rapid descent energy minimization. Peptide modeling
was performed in InsightII (Accelrys, San Diego, CA), a molecular
modeling suite.
To further relax the structure of the cyclic peptide, we
performed all-atom 10 ns equilibrium molecular dynamics
simulation of A1 in GROMACS [41,42] (see Figure 1C for cyclic
peptide structure after 10 ns simulation.) The peptide was solvated
in a rectangular box filled with SPC water molecules [43]. A
chloride ion was added to the system such that the net charge of
the system is zero. OPLSAA force field was used to define
interactions between protein atoms [44]. We employed the
Particle Mesh Ewald (PME) method to calculate the electrostatics
interactions in the system [45,46]. The system was coupled to an
external thermal bath at 300 K with a coupling constant of tT =
0.1 ps [47]. The system pressure was also maintained at 1.0 bar by
an isotropic pressure coupling with time constant tP = 0.5 ps
[47]. In both the peptide redesign and identification of binding
sites, we selected the peptide conformations from the equilibrium
simulation corresponding to 1 ns, 9 ns, and 10 ns, which are
labeled as 1-ns, 9-ns, and 10-ns, respectively.
Putative binding sites on CRIP1. To increase the binding
affinity of the initially identified peptide A1, we needed structures
of peptides docked to CRIP1. To arrive at the CRIP1-peptide
complexes, we docked the three peptides to the 48 CRIP1
conformations derived from NMR (Figure 2). CRIP1 structure
contains a long unstructured N-terminal loop, which include
residues G61 to K76 (Figure 1A). Peptides that docked exclusively
to this loop were excluded in the redesign. We used ZDOCK to
find candidate peptide binding sites on CRIP1 [48,49]. ZDOCK
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modes for proteins based on shape complementarity, desolvation
energy, and electrostatics [48,49].
For each candidate peptide, we identified the dominant binding
modes by clustering them according to their position on the
CRIP1 surface (Figure 2). We first defined the position of the
peptide by the center of mass of its Ca atoms. Then, using a
hierarchical clustering algorithm, we were able to group the
centroids. To find the optimal number of clusters, we first varied
the cutoff (maximum distance between two subnodes that belong
to the same cluster) (Figure 2). In clustering, there are two
competing parameters, the number of clusters and the similarity
between elements within a cluster. In the maximum number of
clusters, each element is itself a cluster, and the single element is
perfectly similar to itself. However, this limit does not reveal the
underlying structure of the data points. In the opposite limit where
we have only one cluster, all objects belong to the same cluster,
which is still not informative. But as shown in Figure 2, the optimal
balance between number of clusters and similarity is attained
when the cutoff is 6.9 A ˚ for 1-ns peptides. For the two other
peptides, the cutoffs were 6.4 and 7.4 A ˚, respectively.
We show in Figure 2 the positions of the peptides that were
docked to CRIP1. Docking sites that belong to the same cluster are
colored similarly. The redesigned peptide A1M, belongs to the
largest cluster.
Peptide redesign. All the CRIP1-peptide complexes derived
from the docking were subjected to redesign. We optimized the
binding of the peptide by computationally mutating each peptide
residue and searching for the peptide sequence with low
DDG=DGMUT 2DGA1, where DGMUT and DGA1 are the free
energies of the redesigned peptide and original peptide A1,
respectively. The detailed methodology of the computational DDG
estimation is described in an earlier study [28,29,50] (see also the
freely accessible server for the DDG estimation ERIS, http://
dokhlab.unc.edu/tools/eris/index.html). ERIS uses a united atom
model, which includes all heavy atoms and polar hydrogen atoms,
to represent proteins. ERIS likewise employs a physical force field
(called Medusa [51]) coupled with fast side-chain packing and
backbone relaxation algorithms. The calculated free energy is a
weighted sum of van der Waals interaction, solvation energy,
hydrogen bonding, and backbone-dependent statistical energy for
any given amino acid and rotamer state. The ERIS DDG
estimation protocol has been benchmarked in earlier study
[28,29] by comparing calculated free energy changes with
experimental values.
We ranked according to DDG values the peptide sequences that
were redesigned from the same backbone conformation and were
docked on the same cluster of binding sites. In Table 2, we show
some representative sequences from the peptide redesign. In these
calculations, the peptide A1M (CLDGGGKGC) exhibited both a
high binding mode rank (most other A1 peptides docked to the
same site) and a low DDG energy, which we selected as the
candidate for experimental verification.
Peptide Synthesis
Peptide on resin. Peptide was synthesized on a Peptide
Synthesizer 433A (Applied Biosystems) using Fmoc chemistry
protocols with HBTU activation (please see schema in Figure S4).
The starting resin was Fmoc-Rink-Amide resin (Elim
Biopharmaceuticals) or Fmoc-Knorr Amide Resin (Case Western
Reserve University). All amino acids used standard side chain
protecting groups, except for the C-terminal lysine residue, which
contained a (4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl (Dde)
functionality protecting the e-amino group to allow orthogonal
synthesis by selective deprotection of the Dde while the peptide
was attached to the resin. The N-terminal cysteine residue was
protected by a Boc group. To provide a linker and a conjugation
site, a Lys and the sequence Gly-Gly-Gly-Ser derived from the
phage sequences immediately downstream of the C7C insert, were
added to the synthesized peptides. After completion of the
synthesis, the peptide resin was washed with DIPEA and DCM
and kept dry for the next reaction.
FITC-peptide on resin. The Dde protecting group was
removed by suspending the resin in 2% hydrazine monohydrate in
DMF (25,100 ml/g, 3,10 times63,60 min). After thorough
washing with DMF and methanol, 2 eq of 5-carboxyfluorescein
was added with 2 eq of TBTU, 2 eq of HOBt, and 8 eq of
diisopropylethylamine in NMP. The coupling of 5-
carboxyfluorescein was allowed to proceed for 24 h at room
temperature. The FITC-peptide on resin was then washed with
NMP, methanol, and kept dry for the next reaction [52].
FITC-peptide. FITC-peptide was cleaved from the resin
support using 2.5% EDT, 1% TIS, 94.5% TFA and 2.0% water
for 2 h at room temperature and precipitated in ether. The FITC-
peptide was purified by reverse phase HPLC (Shimazu LC-20AT,
SPD-10 UV detector) on a Luna 5 m C18(2) column
(250 mm610 mm, Phenomonex Corp.) using a linear gradient
system of 0.1% TFA aqueous solution with an initial concentration of
acetonitrile 5%. The calculated mass was confirmed by mass
spectrometry (PE Biosystem, ProTOF ). FITC-A1 peptide with
sequence NH2-C-L-K-D-N-H-R-S-C-G-G-G-S-K-(FITC)-CONH2:
m/z: 1818.7; calculated mass: C77H107N23O25S2, 1817.7. FITC-B5
peptide with sequence C-Y-D-P-I-W-R-T-C-G-G-G-S-K-(FITC)-
CONH2: m/z: 1898.6; calculated mass: C87H110N20O25S2, 1897.6.
FITC-A1M peptide with sequence NH2-C-L-D-G-G-G-K-G-C-G-
G-G-S-K-(FITC)-CONH2: m/z: 1552.6; calculated mass:
C66H89N17O23S2, 1551.0.
Cyclization of FITC-peptide [53]. FITC-peptide was
resuspended at 0.5-1 mg/ml and oxidized in 10,20% DMSO
aqueous solution adjusted to pH 7 by (NH4)2CO3. At the completion
of the reaction, usually 4,10 hours, the solution was purified by
reversephaseHPLC(Shimazu LC-20AT,SPD-10UVdetector)ona
Luna 5 m C18(2) column (250 mm610 mm, Phenomonex Corp.)
using a gradient system of 0.1% aqueous TFA with an initial
concentration of acetonitrile 5%. The calculated mass was confirmed
by mass spectrometry (PE Biosystem, ProTOF). FITC-cyclic-A1
peptide with sequence NH2-C-L-K-D-N-H-R-S-C-G-G-G-S-K-
(FITC)-CONH2: m/z: 1816.8; calculated mass: C77H105N23O25S2,
1815.7. FITC-cyclic-B5 peptide with sequence C-Y-D-P-I-W-R-T-
C-G-G-G-S-K-(FITC)-CONH2: m/z: 1896.6; calculated mass:
C87H108N20O25S2, 1895.6. FITC-cyclic-A1M peptide with
sequence NH2-C-L-D-G-G-G-K-G-C-G-G-G-S-K-(FITC)-
CONH2: m/z: 1550.6; calculated mass: C66H87N17O23S2, 1549.0.
The synthesis was shown in Scheme 1. Circularization resulted in a
loss of 2 protons as measured by Mass Spec analysis.
Measurement of Binding Affinity
The binding affinity of the peptides for CRIP1 protein was
determined by saturation binding experiments [54,55]. Ninety-six
well plates were coated with 150 ml of PBS buffer containing
100 mg/ml of CRIP1 and incubated overnight at 4uC. The wells
were then washed three times with 50 mM Tris, 150 mM NaCl,
pH 7.5 (TBS) containing 0.1% Tween-20 (TBST), and then each
well filled completely with blocking buffer (TBS containing 0.5%
BSA), incubated at least 1 hour at 4uC, and then rapidly washed 3
times with TBST. Following washing 100 ml of binding buffer
containing different concentrations of FITC-labeled peptides
(ranging from 50 nM to 100 mM) were added to the CRIP1
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After incubation, the plates were washed three times with binding
buffer. The fluorescence intensity in each well was determined on
Infinite M200 Tecan Instrument (Tecan, NC) (Excitation
wavelength: 494 nm, Emission wavelength: 530 nm). The appar-
ent equilibrium dissociation constant, Kd,apparent, was calculated by
non-linear regression using GraphPad Prism (GraphPad Prism 4.0
Software, San Diego, CA). Each data point is the average of three
determinations. Nonspecific binding was defined in the presence of
1 mM unlabeled peptide. All binding experiments (saturation
binding and competitive binding experiments) were conducted
under equilibrium binding conditions and under conditions where
total ligand added was essentially equivalent to the amount of free
ligand after the binding reaction occurred.
Competitive Binding Assay
The binding affinity of the A1 and A1M peptides for CRIP1
protein was directly compared by a competitive binding
experiment [55,56]. Labeled A1M peptide (FITC-A1M) was
competed with increasing concentrations of either unlabeled A1M
peptides or A1 peptide and the IC50 for each peptide calculated.
Ninety-six well plates were coated with 150 ml of PBS buffer
containing 100 mg/ml of CRIP1 and incubated overnight at 4uC.
The wells were then washed 3 times with 50 mM Tris, 150 mM
NaCl, pH 7.5 (TBS) containing 0.1% Tween-20 (TBST), and then
each well filled completely with blocking buffer (TBS containing
0.5% BSA), incubated at least 1 hour at 4uC, and then rapidly
washed 3 times with TBST. Following washing 150 ml of binding
buffer containing FITC-A1M peptides of 10 mM and appropriate
dilutions of unlabeled A1 and A1M peptides (ranging from 0 to
300 mM) were added to the CRIP1 containing wells and incubated
for 1 hour at 37uC with rocking. After incubation, the plates were
washed three times with binding buffer. The fluorescence intensity
in each well was determined on Infinite M200 Tecan Instrument
(Tecan, NC) (Excitation wavelength: 494 nm, Emission wave-
length: 530 nm). Ki was calculated by non-linear regression with
one binding site using GraphPad Prism (GraphPad Prism 4.0
Software, San Diego, CA). Each data point is the average of three
determinations, shown in Figure 4B. Data was analyzed using
several different binding models and was found to only fit a one
binding site model. When no competitor was added the data point
was graphed as 0.1 nM to satisfy software requirements. This has
no effect on calculations of the IC50’s.
Supporting Information
Figure S1 The cDNA and amino acid sequences of CRIP1.
After cloning, the insert was confirmed by sequencing and the
deduced amino acid sequences for the human CRIP1 shown in
Figure 1S. Excluding the vector sequence and the poly A region,
the cDNA insert is 243 base pairs in length. The start site for
transcription is at nucleotide position 73 (not shown in figure) with
the start of translation at nucleotide position 162. This open
reading frame expresses the amino acids encoding the His-tag (nt:
186–242) and encoding an enterokinase clevage site (nt: 246–260).
The sequences encoding the human CRIP1 protein begin at
nucleotide 273 and continue through nucleotide 503. Translation
of these sequences results in a polypeptide 114 amino acids in
length, the majority of which, 77 amino acids, make up CRIP1
protein. The start (ATG) and stop (TAA) codons are underlined.
The sequence of nonadjacent 6 histidines on HAT epitope is in
bold. The poly A tail at the end is not shown.
Found at: doi:10.1371/journal.pcbi.1000138.s001 (0.80 MB TIF)
Figure S2 CRIP1 purity. Comassie Blue stained-SDS-PAGE
analysis of CRIP1 lysate and elutions after purification. Lane 1:
standard molecular marker; Lane 2: lysate before incubation with
Resin; Lane 3: lysate after incubation with Resin; Lane 4,5:
fractions through Clontech TALON CellThru column.
Found at: doi:10.1371/journal.pcbi.1000138.s002 (1.30 MB TIF)
Figure S3 Relative estimates of peptide affinity for CRIP1.
Phage binding against immobilized CRIP-1.
Found at: doi:10.1371/journal.pcbi.1000138.s003 (0.38 MB TIF)
Figure S4 Synthesis of FITC-peptides. Please see Methods for
detailed description.
Found at: doi:10.1371/journal.pcbi.1000138.s004 (0.92 MB TIF)
Figure S5 Sequences of redesigned peptides. Sequence motifs of
the redesigned peptides for the starting peptide structure models 1-
ns, 9-ns, and 10-ns. The rank pertains to the order putative the
binding site on CRIP1 defined from clustering.
Found at: doi:10.1371/journal.pcbi.1000138.s005 (0.68 MB TIF)
Figure S6 Residue preference without CRIP context. To verify
that the observed preference for Gly in some sites in the peptide is
not due to a bias in the force field, we employed the protocol to
find the optimal peptide sequence when the peptide is not bound
to CRIP1. We used 50 independent redesign runs. The preferred
sequences are expectedly highly polar which maximize the peptide
solvation energy.
Found at: doi:10.1371/journal.pcbi.1000138.s006 (0.09 MB TIF)
Table S1 Analysis of CRIP1.
Found at: doi:10.1371/journal.pcbi.1000138.s007 (0.04 MB
DOC)
Table S2 Contribution of individual energy terms to the DDGo f
the redesigned peptide A1M CLDGGGKGC.
Found at: doi:10.1371/journal.pcbi.1000138.s008 (0.04 MB
DOC)
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